

*In the claims:*

The following claims have been amended to read as follows:

B2

16. The method according to claim 15 further comprising contacting the hematopoietic stem or progenitor cells with GM-CSF.

23. The method according to claim 15 wherein the flt3-ligand is human flt3-ligand.

B3

24. The method according to claim 16 wherein the flt3-ligand is human flt3-ligand.

25. The method according to claim 16 wherein the GM-CSF is human GM-CSF.

2B4

31. The method of claim 29, further comprising contacting the dendritic cells with GM-CSF.

32. The method of claim 31, wherein the GM-CSF is human GM-CSF.

B5

36. The method according to claim 29 wherein the flt3-ligand is human flt3-ligand.

### REMARKS

1. Pending Claims

Applicants acknowledge that claims 15, 16, 23-25, 29-32 and 36 are pending in the application with claims 15 and 29 being in independent form. Claims 16 and 31 have been amended to limit the claims to GM-CSF, which is the elected species. Claims 23, 24, 25 and 36 have been amended to delete reference to "recombinant" proteins based on the Examiner's comments in the Office Action. Claim 32 has been amended to specify the that the GM-CSF is human GM-CSF.

2. Related Applications

Applicants have amended the specification to update the Related Applications section.

3. Review of Application